

## Scientific Programme

### Wednesday, 12 October 2022

16.00 Registration open

### Thursday, 13 October 2022

09.30 - 11.00 **ESU Course: How to write a scientific paper or a grant proposal**  
To be confirmed

11.00 - 13.00 **Workshop I:**  
**Single-cell RNA sequencing-technical workshop**  
S. Salcher (Innsbruck, AT)

11.00 – 13.00 **Workshop II:**  
**Recent scientific developments in penile cancer in connection with clinical pathology research:**  
Clinician : R. Pichler (Innsbruck, AT)  
Biologist : S. Lohse (Homburg, DE)  
Pathologist : M. Fiorentino (Bologna, IT)

13.00 - 13.30 **Lunch**


13.30 - 14.00 **Opening**

14.00 - 15.45 **Session I: Tumour microenvironment in uro-oncology**  
Chairs: N. Sampson (Innsbruck, AT)  
K.A. Tasken (Oslo, NO)  
G. Van Der Pluijm (Leiden, NL)

14.00 - 14.25 **Adoptive T cell therapy to target urological cancers**  
R. Debets (Rotterdam, NL)

14.25 - 14.45 **How to investigate immune microenvironment in xenograft mouse models**  
E. Rusten (Oslo, NO)


14.50 - 15.45 **Oral presentations selected from the best abstracts (4)**




- 15.45 - 16.15**      **Coffee break**
- 16.15 - 18.20**      **Session II: Metabolic landscape of urological diseases**  
Chairs:            I. Ahmad, (Glasgow (GB))  
                      J. Ceraline (Illkirch, FR)  
                      I. Eder (Innsbruck, AT)
- 16.15 - 16.35**      **Gut microbiota and therapy response in urological malignancies**  
To be confirmed
- 16.35 - 17.00**      **Mitochondrial dysfunction in prostate cancer progression**  
A. Papachristodoulou (New York, US)
- 17.00 - 17.20**      **Metabolic reprogramming in kidney cancer**  
M. Schwab (Stuttgart, DE)
- 17.20 - 18.20**      **Oral presentations selected from the best abstracts (5)**

## Friday, 14 October 2022

- 08.30 - 10.45**      **Session III: Hereditary urological tumour predisposition - challenges for precision medicine**  
Chairs:            K. Junker (Homburg, DE)  
                      H. Leung, Glasgow (GB)
- 08.30 - 08.50**      **Molecular alterations in urothelial carcinoma in Lynch syndrome**  
M. Moschini (Milan, IT)
- 08.50 - 09.30**      **Genetic profiling in renal cell cancer: Implications for individual treatment**
- 08.50 - 09.02**      **Basics and pathology**  
A. Hartmann (Erlangen, DE)
- 09.02 - 09.14**      **Clinical consequences**  
U. Capitanio (Milan, IT)
- 09.14 - 09.30**      **Discussion**
- 09.30 - 09.50**      **PARP inhibition beyond prostate cancer: Targeting the DNA damage response in 2immuno-oncology**  
R. Chabanon (London, GB)



- 09.50 - 10.45**      **PARP inhibitors as combination partners in prostate cancer: What makes sense**
- 09.50 - 10.02      **Molecular basis**  
D. Olmos (Madrid, ES)
- 10.02 - 10.14      **Clinical overview**  
A. Heidenreich (Cologne, DE)
- 10.15 - 10.25      **Liquid biopsy by analysis of CTCs for patient stratification for olaparib therapy in mCRPC (friendly support from Astra Zeneca)**  
F. Santer (Innsbruck, AT)
- 10.25 - 10.45      **Discussion**
- 10.45 - 11.15**      **Coffee break**
- 11.15 - 12.30**      **Oral presentations selected from the best abstracts (6)**  
Chairs:            E. Martens-Uzunova (Rotterdam, NL)  
                      M. Puhr (Innsbruck, AT)
- 12.30 - 13.15**      **Lunch**
- 13.15 - 15.00**      **Poster Session 1**
- 15.00 - 15.40**      **Session IV: Recent advances in diagnostics**  
Chairs:            A. Hartmann (Erlangen, DE)  
                      C. Jeronimo (Porto, PT)  
                      A. Vlahou (Athens, GR)
- 15:00 - 15:20**      **Immunoscore in urothelial cancer**  
T. Gevaert (Leuven, BE)
- 15.20 - 15.40**      **When to use miRNA test in testicular cancer**  
K.P. Dieckmann (Hamburg, DE)
- 15.40 - 16.10**      **Coffee break**
- 16.10 - 16.40**      **The impact of clinical biomarkers in metastatic hormonsensitive PCa (friendly support from Astellas)**  
J. Bektic (Innsbruck, AT)  
Chairs:            I. Heidegger (Innsbruck, AT)



**16.40 - 17.40**

**Oral presentations selected from the best abstracts (5)**

Chairs: A. Hartmann (Erlangen, DE)  
C. Jeronimo (Porto, PT)  
A. Vlahou (Athens, GR)

**Saturday, 15 October 2022**

**08.30 - 10.25**

**Session V: The next generation of targets in urology**

Chairs: Z. Culig (Innsbruck, AT)  
M. Colecchia (Milan, IT)  
M. Kafka (Innsbruck, AT)

**08:30 - 08.50**

**Towards biologically-driven decisions in the treatment of urological cancers (basic research)**

M. Kruithof-de Julio (Berne, CH)

**08.50 - 09.40**

**Molecular tumour board: Targetable mutations – an individualized patient approach**

**08.50 - 08.55**

**Patient case**

A.K. Lindner (Innsbruck, AT)

**08.55 - 09.07**

**Researcher**

M. Toma (Bonn, DE)

**09.07 - 09.20**

**Clinician**

M. Pichler (Graz, AT)

**09.20 - 09.40**

**Discussion**

**09.45 - 10.25**

**Oral presentations selected from the best abstracts (3)**

**10.25 - 10.50**

**Coffee break**

**10.50 - 12.00**

**Poster session 2**

**12.00 - 12.30**

**Chopin Award Session**

**12.30 - 12.50**

**Closing remarks, awards**